Analysis

Pulled Pain Pill, Opioid Rates Show Need For Research

Law360, New York (July 10, 2017, 10:31 PM EDT) -- Endo International PLC’s recent decision to yank its painkiller Opana ER from the market, following pressure from the U.S. Food and Drug Administration to stop sales of the abuse-linked drug and as prescriptions of opioids remain high in many parts of the country, points to the need for more research in treating both pain and opioid addiction.

The FDA took the step a month ago formally requesting the drugmaker withdraw a prescription opioid due to abuse risks, in a move attorneys say was not only unprecedented...
To view the full article, register now.